Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Generation Bio Co. (GBIO:NASDAQ), powered by AI.
Generation Bio Co. is currently trading at $5.34. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Generation Bio Co. on Alpha Lenz.
Generation Bio Co.'s P/E ratio is -0.3.
“Generation Bio Co. trades at a P/E of -0.3 (undervalued) with modest ROE of -91.0%.”
Ask for details →Generation Bio Co. is a biotechnology company dedicated to developing novel gene therapies. The primary focus of Generation Bio is on its transformative non-viral delivery platform, which aims to advance the treatment of a variety of genetic disorders. This non-viral approach distinguishes itself from traditional viral vector methods by potentially offering enhanced safety and the ability to deliver gene therapies repeatedly. Generation Bio targets trailblazing treatment avenues in genetic and rare diseases, particularly those impacting the liver and eye. The company's innovative platform seeks to expand the therapeutic possibilities by addressing the limitations of existing gene therapy technologies. Operating in the dynamic and rapidly evolving biotechnology sector, Generation Bio Co. plays a significant role in the cutting-edge field of genomic medicine. Its efforts could reshape the landscape for therapeutic interventions, making gene therapy more accessible and adaptable across multiple genetic conditions. As the biotechnology industry continues to push the boundaries of traditional medicine, Generation Bio stands at the forefront, highlighting the critical shift towards innovative treatment modalities.
“Generation Bio Co. trades at a P/E of -0.3 (undervalued) with modest ROE of -91.0%.”
Ask for details →Generation Bio Co. (ticker: GBIO) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 115 employees. Market cap is $36M.
The current price is $5.34 with a P/E ratio of -0.27x and P/B of 0.41x.
ROE is -91.02% and operating margin is -398.11%. Annual revenue is $20M.